Yolanda Aladro1, Rodrigo Terrero2, Marta Cerezo2, Ricardo Ginestal3, Lucía Ayuso4, Virginia Meca-Lallana5, Jorge Millán6, Laura Borrego7, Marisa Martinez-Ginés8, Luisa Rubio4, Clara de Andrés8, Ambrosio Miralles9, Cristina Guijarro10, Elena Rodríguez-García11, José Manuel García-Dominguez12, Carmen Muñoz-Fernández13, Carlos López de Silanes14, Mayra Gómez15, Israel Thuissard16, María Cerdán17, Itziar Palmí5, Luis Felipe Díaz-Garzón10, Jose Meca-Lallana17. 1. Multiple Sclerosis Unit, Department of Neurology, Getafe University Hospital, European University of Madrid, Spain. Electronic address: yolanda.aladro@salud.madrid.org. 2. Multiple Sclerosis Unit, Department of Neurology, Getafe University Hospital, European University of Madrid, Spain. 3. Department of Neurology, Universitary Hospital "Fundación Jiménez Díaz", Madrid, Spain. 4. Department of Neurology, Universitary Hospital "Príncipe de Asturias", Alcalá de Henares, Madrid, Spain. 5. Department of Neurology, Universitary Hospital "La Princesa", Madrid, Spain. 6. Department of Neurology, General Hospital "La Mancha Centro", Alcázar de San Juan, Ciudad Real, Spain. 7. Department of Neurology, Universitary Hospital "Fundación de Alcorcón", Madrid, Spain. 8. Department of Neurology, University Hospital "Gregorio Marañón", Madrid, Spain. 9. Department of Neurology, University Hospital "Infanta Sofía", San Sebastián de los Reyes, Madrid, Spain. 10. Department of Neurology, Hospital "Santa Bárbara", Puertollano, Ciudad Real, Spain. 11. Department of Neurology, Universitary Hospital "Severo Ochoa", Leganés, Madrid, Spain. 12. Department of Neurology, Hospital Central de la Defensa "Gómez Ulla", Madrid, Spain. 13. Department of Neurology, Hospital Complex Torrecárdenas, Almería, Spain. 14. Department of Neurology, Torrejon Universitary Hospital, Madrid, Spain. 15. Department of Neurology, Universitary Hospital "Infanta Leonor", Madrid, Spain. 16. Department of Statistic, European University of Madrid, Spain. 17. Department of Neurology, MS Unit, Universitary Clinic Hospital "Virgen de la Arrixaca" (IMIB-Arrixaca), Murcia, Spain; Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM, Universidad Católica San Antonio de Murcia, Spain.
Abstract
OBJECTIVE: To estimate the seroprevalence of anti-JCV antibodies, seroconverting rates and evolution of antibody levels in a multiple sclerosis (MS) Spanish cohort. METHODS: Multicenter, retrospective cross-sectional and longitudinal study. The JCV seroprevalence was analyzed in 711 MS patients by using 1st (STRATIFY-1) and 2nd generation (STRATIFY-2) two-step ELISA over 2.65 (±0.97) years. Seroconversion rate was obtained over 2 samples from 314 patients, and index stability from 301 patients with 3 or more samples available. The effect of each ELISA generation, demographics, clinical characteristics and therapy on seroprevalence was assessed by logistic regression. RESULTS: The overall anti-JCV seroprevalence was 55.3% (51.6-58.9), similar across regions (p=0.073). It increased with age (p<0.000) and when STRATIFY-2 was used (60.5%, p=0.001). Neither sex nor immunosuppressive therapy had any influence. Yearly seroconversion rate was 7% (considering only STRATIFY-2). Serological changes were observed in 24/301 patients, 5.7% initially seropositive reverted to seronegative and 7% initially seronegative changed to seropositive and again to seronegative, all these cases had initial index values around the assay's cut-off. CONCLUSIONS: JCV seroprevalence in Spanish MS patients was similar to that reported in other European populations. Changes in serostatus are not infrequent and should be considered in clinical decisions.
OBJECTIVE: To estimate the seroprevalence of anti-JCV antibodies, seroconverting rates and evolution of antibody levels in a multiple sclerosis (MS) Spanish cohort. METHODS: Multicenter, retrospective cross-sectional and longitudinal study. The JCV seroprevalence was analyzed in 711 MSpatients by using 1st (STRATIFY-1) and 2nd generation (STRATIFY-2) two-step ELISA over 2.65 (±0.97) years. Seroconversion rate was obtained over 2 samples from 314 patients, and index stability from 301 patients with 3 or more samples available. The effect of each ELISA generation, demographics, clinical characteristics and therapy on seroprevalence was assessed by logistic regression. RESULTS: The overall anti-JCV seroprevalence was 55.3% (51.6-58.9), similar across regions (p=0.073). It increased with age (p<0.000) and when STRATIFY-2 was used (60.5%, p=0.001). Neither sex nor immunosuppressive therapy had any influence. Yearly seroconversion rate was 7% (considering only STRATIFY-2). Serological changes were observed in 24/301 patients, 5.7% initially seropositive reverted to seronegative and 7% initially seronegative changed to seropositive and again to seronegative, all these cases had initial index values around the assay's cut-off. CONCLUSIONS: JCV seroprevalence in Spanish MSpatients was similar to that reported in other European populations. Changes in serostatus are not infrequent and should be considered in clinical decisions.
Authors: Harald Hegen; Michael Auer; Gabriel Bsteh; Franziska Di Pauli; Tatiana Plavina; Janette Walde; Florian Deisenhammer; Thomas Berger Journal: PLoS One Date: 2017-03-20 Impact factor: 3.240
Authors: Harald Hegen; Janette Walde; Gabriel Bsteh; Michael Auer; Sebastian Wurth; Anne Zinganell; Franziska Di Pauli; Florian Deisenhammer; Thomas Berger Journal: Front Immunol Date: 2018-10-25 Impact factor: 7.561
Authors: Christopher M Dwyer; Vilija G Jokubaitis; Jim Stankovich; Josephine Baker; Jodi Haartsen; Helmut Butzkueven; Adriana Cartwright; Neil Shuey; Yara Dadalti Fragoso; Louise Rath; Olga Skibina; Kylie Fryer; Ernest Butler; Jennifer Coleman; Jennifer MacIntrye; Richard Macdonell; Anneke van der Walt Journal: Ther Adv Neurol Disord Date: 2021-04-16 Impact factor: 6.570
Authors: Robert Bonek; Wojciech Guenter; Robert Jałowiński; Anna Karbicka; Anna Litwin; Maciej Maciejowski; Radosław Zajdel; Karolina Zajdel; Veronique Petit; Konrad Rejdak Journal: J Clin Med Date: 2021-05-06 Impact factor: 4.241